Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort.
Adult
Antidepressive Agents
/ therapeutic use
Cohort Studies
Depressive Disorder
/ drug therapy
Drug Prescriptions
/ statistics & numerical data
Drug Utilization
/ statistics & numerical data
Female
France
Humans
Incidence
Pregnancy
Pregnancy Complications
/ drug therapy
Prevalence
Selective Serotonin Reuptake Inhibitors
/ therapeutic use
Antidepressant drugs
Drug utilisation study
Pregnancy
Psychotropic drugs
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
24
11
2017
accepted:
22
05
2018
pubmed:
29
5
2018
medline:
11
2
2020
entrez:
28
5
2018
Statut:
ppublish
Résumé
Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France. We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied. During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed. Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France.
METHODS
METHODS
We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied.
RESULTS
RESULTS
During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed.
CONCLUSIONS
CONCLUSIONS
Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.
Identifiants
pubmed: 29804133
doi: 10.1007/s00406-018-0906-2
pii: 10.1007/s00406-018-0906-2
doi:
Substances chimiques
Antidepressive Agents
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-849Références
Obstet Gynecol. 2004 Apr;103(4):698-709
pubmed: 15051562
Obstet Gynecol. 2005 Nov;106(5 Pt 1):1071-83
pubmed: 16260528
JAMA. 2006 Feb 1;295(5):499-507
pubmed: 16449615
Arch Pediatr Adolesc Med. 2006 Feb;160(2):173-6
pubmed: 16461873
Arch Gen Psychiatry. 2006 Aug;63(8):898-906
pubmed: 16894066
Am J Obstet Gynecol. 2007 Jun;196(6):544.e1-5
pubmed: 17547888
Am J Obstet Gynecol. 2008 Feb;198(2):194.e1-5
pubmed: 17905176
Eur J Clin Pharmacol. 2009 Aug;65(8):839-46
pubmed: 19365629
Obstet Gynecol. 2011 Jul;118(1):111-20
pubmed: 21646927
Epidemiology. 2011 Nov;22(6):848-54
pubmed: 21900825
Best Pract Res Clin Obstet Gynaecol. 2014 Jan;28(1):37-48
pubmed: 24100223
PLoS One. 2014 Apr 04;9(4):e93870
pubmed: 24705674
J Manag Care Spec Pharm. 2014 Jun;20(6):631-7
pubmed: 24856601
N Engl J Med. 2014 Jun 19;370(25):2397-407
pubmed: 24941178
Dan Med J. 2014 Sep;61(9):B4916
pubmed: 25186551
BJOG. 2015 Jun;122(7):1010-20
pubmed: 25352424
Lancet. 2014 Nov 15;384(9956):1775-88
pubmed: 25455248
Depress Anxiety. 2015 Jun;32(6):426-36
pubmed: 25703355
JAMA. 2015 Jun 2;313(21):2142-51
pubmed: 26034955
BJOG. 2016 Nov;123(12):1919-1928
pubmed: 26374344
Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):32-6
pubmed: 26435496
PLoS One. 2015 Dec 14;10(12):e0144474
pubmed: 26657647
JAMA Pediatr. 2016 Feb;170(2):117-24
pubmed: 26660917
Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):770-7
pubmed: 27018245
Br J Clin Pharmacol. 2016 Aug;82(2):566-7
pubmed: 27197980
JAMA. 2016 May 24-31;315(20):2230-2
pubmed: 27218634
Fundam Clin Pharmacol. 2016 Oct;30(5):476-82
pubmed: 27324073
Int J Clin Pract. 2016 Sep;70(9):744-51
pubmed: 27484351
Reprod Toxicol. 2016 Dec;66:31-43
pubmed: 27667009
J Affect Disord. 2017 Feb;209:140-146
pubmed: 27914247
Child Abuse Negl. 2017 Jan;63:192-201
pubmed: 27940036
J Midwifery Womens Health. 2017 May;62(3):317-328
pubmed: 28485526